The Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BRS; Abbott Vascular, Santa Clara, CA, USA) promises vascular repair maintaining lumen diameter and restoring vasomotion thereby reducing plaque volume. This technique allows an option for bypass surgery thereafter ("leaving nothing behind") [1] . Concerns arose from some trials and registries reporting higher rates of stent thrombosis and restenosis, although data are not unequivocal [2, 3] . So far, randomized controlled trials with BRS addressed simple and intermediate lesions. Whether BRS are also suited for more complex lesions is less known [4] . However, from a theoretical point of view, patients with more complex and especially long or multiple lesions may benefit most in the long-term from a therapy with BRS. The presented case was of a young patient with ST-elevation myocardial infarction (STEMI) undergoing multiple percutaneous coronary interventions (PCI) and BRS implantation.
A 55-year-old man was admitted to our hospital with an inferior STEMI, with peak high sensitivity--troponin (hsT) of 5333 ng/L and creatine kinase of 2131 U/L (normal value respectively < 14 ng/L and < 190 U/L). Coronary angiography revealed diffuse triple-vessel disease with subtotal occlusion of the distal right coronary artery (RCA, Fig. 1A , white double circle), long significant lesions of the left circumflex artery (LCX) and marginal branch (Fig. 1B) as well as severe stenosis of the left anterior descending artery (LAD) and the first diagonal branch (D1) (Fig. 1C) . Left ventricular ejection fraction was normal with inferior hypokinesia. First, a 3.0 × 23 mm everolimus-eluting bioresorbable vascular scaffold (BRS, Absorb ® , Abbott Vascular, Santa Clara, CA, USA) was implanted in the distal RCA ("culprit lesion") followed by a 3.5 × 18 mm BRS in the mid RCA. Proximally to the latter, a drug-eluting stent (Xience Alpine 4.0 × × 28 mm, Abbott) was implanted due to the large vessel size (Fig. 1D) , with no overlapping of the previous implanted BRS and no signs of dissection at the optical coherence tomography (OCT) control (Fig. 1E ). The patient refused surgical revascularization of the remaining lesions and the residual SYNTAX Score after PCI was 28. Therefore, the following day, the marginal branch and proximal LCX were stented again using two BRS (2.5 × × 28 mm and 3.0 × 28 mm) (Fig. 1F) . Fluoroscopy showed a proximal-edge dissection, and the OCT confirmed a 4 mm long dissection (insert in Fig. 1F and Fig. 1G ; Supplemental Video 1 -see journal website) that was treated with a 3.0 × 8 mm BRS with optimal result (Supplemental control coronary angiography showed an optimal result after PCI. At that time four additional BRS were implanted in the mid-LAD (3.0 × 23 mm and 2.5 × 23 mm) and in the D1 (3.0 × 12 mm and 2.5 × 18 mm) (Fig. 1H ) with no evidence of dissection at the following OCT control ( Fig. 1 ; Supplemental Video 3 -see journal website). Lesion preparation was always performed using compliant balloon with increasing diameter whereas needed, while post-dilatation was always carried out using non-compliant balloon with high inflation pressure. 181 mm-BRS-implantation achieved a full revascularization.
After 3 months the patient was again admi tted to our hospital with an acute non-STEMI with a peak hsT of 569 ng/L and creatine kinase of 193 U/L. Coronary angiogram revealed a mid-proximal LAD stenosis (Fig. 1J ) adjacent to the proximal LAD BRS (scaffold restenosis, according to the current definition within 5 mm proximal and distal to the stent/scaffold [5] ). The lesion was treated with a sirolimus drug-eluting stent. Re-analysis of the previously performed final angiography and OCT of the respecting BRS showed no signs of strut malapposition, edge dissection or thrombus formation. Therefore, the underlying mechanism of this stenosis outside the scaffold was most likely related to the recommended post-dilatation (in our case a 3.0 × 15 mm non-compliant balloon at 24 bar) when using BRS with consequent micro-injury of the intima ("geographical miss") ( Fig. 1K and insert,  Fig. 1L ) rather than a "classical scaffold stenosis".
"Full Plastic-Jacket" using BRS is feasible and could be an option for patients with a diffuse disease, however, future studies are necessary to prove long-term benefit of this new therapeutic option [6] . BRS implantation in STEMI patients represents a potential option with a high procedural success rate [7] . Nevertheless, due to lesion preparation and post-dilatation, which are mandatory to achieve an optimal result with BRS [8] , there might be a potentially higher risk of early de novo stenosis or scaffold stenosis adjacent or outside the BRS.
